Celgene Fact Sheet

PROFILE

Celgene Corporation, as a leader in global biotechnology, has built an integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.

BUILDING ON SUCCESS WITH THE PHARMION ACQUISITION

- Advances Celgene's goal to become the leader in blood cancers
- Leverages Celgene's clinical, regulatory and commercial potential worldwide
- Creates substantial opportunity to maximize VIDAZA's potential through combination studies as a result of two great companies coming together
- Accelerates long-term operational and financial opportunities
- Broadens portfolio of disease-altering therapies
- Complements and expands Celgene's industry leading programs for safety, access and patient support

REVENUE, R&D, & EPS



NEWS EVENTS MARCH 2008

CELGENE ACQUIRES PHARMION

In March 2008, Celgene Corporation completed its acquisition of Pharmion Corporation. This combination of two outstanding organizations came about as the result of the hard work and talent of each and every employee. Celgene plans to build on both organization's accomplishments to reach the goal of becoming a leading global biopharmaceutical company while improving the lives of patients with unmet medical needs.

This acquisition brings together three disease-altering therapies in REVLIMID®, THALOMID® and VIDAZA® and provides opportunities to build a new kind of organization focused on critical areas of medicine, turning incurable cancers into chronic manageable diseases and helping healthcare providers deliver positive outcomes for their patients.

DRIVING GLOBAL EXPANSION

February 2008	• REVLIMID receives Orphan Drug Status in Japan for multiple indications • VIDAZA accepted for review by EMEA for high-risk MDS
January 2008	• THALIDOMIDE PHARMION Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency • REVLIMID receives marketing authorization approval from Australian Therapeutic Good Administration for treatment of Multiple Myeloma • REVLIMID receives marketing authorization approval from Canadian Therapeutic Products Directorate for treatment of deletion 5q MDS
December 2007	• More than 113 abstracts presented at ASH 2007; 25 oral presentations including updated clinical data for REVLIMID in newly diagnosed multiple myeloma, non-deletion 5q MDS, chronic lymphocyctic leukemia (CLL) and non-hodgkin's lymphoma (NHL)
September 2007	• REVLIMID, in combination with dexamethasone, was compendia listed for newly diagnosed multiple myeloma
August 2007	• Pharmion released landmark survival data on VIDAZA from a Phase III controlled trial in higher risk MDS patients, VIDAZA showed a survival benefit of 9.4 months compared to conventional care
June 2007	• REVLIMID granted full marketing authorization by the European Commission for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy

Revlimid® (lenalidomide) capsules

THALOMID® (thalidomide) Capsules

Vidaza® azacitidine for injection

ORAL ANTI-INFLAMMATORY FRANCHISE

In February, Celgene reported updated clinical data on CC-10004 (Apremilast) in patients with moderate-to-severe plaque-type psoriasis evaluating efficacy, safety and quality of life improvement. Based on those results, Apremilast is clinically effective based on PASI score and DLQI measures. Those results have led to increasing the dosage level and extending the duration of use for six months in a Phase II study later this year. The Company will advance its clinical and regulatory efforts for Apremilast in psoriasis and psoriatic arthritis as well as initiate new studies in rheumatic, dermatologic and inflammatory diseases.

CELGENE CORPORATION

86 Morris Avenue • Summit, NJ 07901 • P: 908-673-9000 • F: 908-673-9001 • www.celgene.com

PRODUCT PIPELINE



IMiDs® Compounds:
- REVLIMID®: Multiple Myeloma
- REVLIMID: MDS deletion 5q
- REVLIMID: MDS
- REVLIMID: CLL
- REVLIMID: NHL
- REVLIMID: Solid Tumors
- Pomalidomide (CC-4047): Myelofibrosis
- Pomalidomide (CC-4047): Multiple Myeloma
- Pomalidomide (CC-4047): Solid Tumors
- Pomalidomide (CC-4047): Sickle Cell Disease
- CC-11006: MDS
- CC-10015: Rheumatology

VIDAZA® (azacitidine):
- MDS
- AML
- Solid Tumors
- MDS/AML (Oral azacitidine)

THALOMID®:
- Multiple Myeloma (US)
- ENL (US)

Thalidomide Pharmion™ 50 MG:
- Multiple Myeloma
- Other Cancer

AMRUBICIN:
- SCLC
- SCLC w/ Cisplatin

Anti-Inflammatory:
- Apremilast (CC-10004): Psoriasis
- Apremilast (CC-10004): Psoriatic Arthritis
- Apremilast (CC-10004): Behcet's Disease
- CC-11050: Inflammatory Diseases

ALKERAN®:
- Multiple Myeloma
- Ovarian Cancer

Ritalin®/FOCALIN™:
- FOCALIN: ADHD
- Ritalin LA®: ADHD
- FOCALIN XR™: ADHD

HDAC Inhibitor (MGCD0103):
- Pancreatic Cancer (w/ gemcitabine)
- Solid Tumors (w/ docetaxol)
- w/ Vidaza in MDS/AML
- w/ Vidaza in lymphoma
- Hodgkin's lymphoma

Kinase Inhibitors:
- JNK 930: Fibrotic Diseases
- p38: Inflammatory Diseases

Activin Inhibitor:
- ACE-011: Cancer-related bone loss

Stem Cells and Tissue Products:
- LifebankUSA: Private Stem Cell Banking
- UCB + HPDSC: Transplants
- PDA-001: Autoimmune/Cancer
- BIOVANCE and Acelegraft™

The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.

INVESTOR CONTACT INFORMATION

Brian Gill
Vice President
Corporate Communications
Email: bgill@celgene.com

Mary Ann Ondish
Assoc. Director
Investor Relations
Email: maondish@celgene.com

CELGENE EXECUTIVE OFFICERS

Sol J. Barer, Ph.D.
Chief Executive Officer

Robert J. Hugin
President and COO

David W. Gryska,
Senior Vice President and CFO

ANALYST COVERAGE

Alliance Bernstein
Banc of America
Bear Stearns
BMO Capital Markets
Citigroup Smith Barney
Cowen
Credit Suisse Securities
Friedman, Billings, Ramsey
Goldman Sachs
Jeffries
JMP Securities
JP Morgan Chase
Lazard Capital Markets
Leerink Swan
Lehman Brothers
Merrill Lynch
Morgan Stanley
Robert W. Baird
Rodman & Renshaw
Thomas Weisel Partners
UBS
Wachovia
William Blair & Co

INVESTMENT CONSIDERATIONS

- Profitable and accelerating revenue growth supporting development of multiple clinical compounds across several high potential programs
- Lead clinical candidates REVLIMID and VIDAZA offer near-term life transforming potential to turn incurable cancers into chronic diseases
- Cutting edge research in cellular signaling technology delivering next generation therapies with potential to change standard of care
- Strong, evolving intellectual property estate supporting a broad, deep, proprietary pipeline addressing large, international commercial opportunities
- Financial strength with over $2.5 billion in cash and marketable securities positioned to support long-term growth strategy
- Effective senior management team experienced in successful execution of corporate strategies